Colorectal cancers constitute approximately 10% of all cancer cases (1). Almost 1,000,000 patients are diagnosed with colorectal cancer worldwide each year, and almost 500,000 people die from this disease annually. Colorectal cancer is the third most common type of cancer in both sexes; it is the second most common cause of death due to cancer in men and the third most common cause of death due to cancer in women (2). Although developments in both the surgical and oncological treatment methods of patients with colorectal cancer make a positive contribution to the survival of patients, the lack of prognostic parameters to predict the effectiveness of treatment planning is still a major problem.
surnames of the patients; hospital protocol numbers; age; gender; address; telephone number; and identifying information, such as data on demographic characteristics, dates of surgery, the operation and perioperative period information (such as local recurrence, tumor histological type, differentiation, tumor size, the number of lymph nodes affected, the involvement of local invasion, vascular invasion, perineural invasion, and positive surgical margins) were obtained from patient files, hospital information system, and pathology reports. The data were analyzed retrospectively.
The current condition of the surviving patients was determined according to the findings of the last follow-up. The final status of the population whose last follow-up date was more than 6 months before were investigated by telephone or from the population directorate. Staging was done according to the criteria of the American Joint Committee on Cancer (AJCC) 2010 staging of colon and rectal cancer. All tissue samples were taken from surgical excision materials. Paraffin-blocked tissue samples of patients were obtained from the archives of the Department of Pathology.
Immunohistochemical Staining of E2F1
Tissue sections of the 82 patients' formalin-fixed 5-6-micron paraffin blocks were transferred to poly-L-lysine coated slides for immunohistochemical studies. The tissue sections were deparaffinized with xylol after standing for an hour in the incubator and then dehydrated with alcohols in rising degree (4 times for 2 min). Endogenous peroxidase activity was blocked with hydrogen peroxide. Tissues were heated with Ethylenediaminetetraacetic acid (EDTA) buffer in the microwave 3 times for 10 min and then allowed to cool for 5 min. The tissues were washed with phosphate buffered saline (PBS). E2F1 antibody (Santa Cruz Biotechnology, USA, dilution 1:100, incubation time 30 min) was added and allowed to stand in the refrigerator overnight. In the next step, the tissues were washed with tris-buffered saline (TBS, pH=7.4). Antigen-antibody binding was made visible by being incubated with biotinylated antirabbit antibody, streptavidin, Avidin-Biotin Complex (ABC) with Horseradish Peroxidase (HRP) solution, and diaminobenzidine for 10 min, in that order. They were counterstained with hematoxylin (Mayer). Then, the washed preparations were closed with a coverslip instilled with balsam.
Immunohistochemical Evaluation of E2F1
For the positive control, internal staining of the tissue was evaluated for immunohistochemical staining. Tonsil tissue was used as a positive control. For the nuclear staining of E2F1, 500 cells were counted under 10× magnification and were classified as mild, moderate, and severe according to the severity of staining (Figure 1 ).
Statistical Analysis
Data were evaluated with the IBM Statistical Package for the Social Sciences 20 statistical package program (IBM Corp.; Armonk, NY, USA). The mean, percentage, and standard deviation were given as descriptive statistics. Quantitative variables were compared with the normal distribution of the ShapiroWilk test. Comparisons between groups according to the normality of variables were done with Student's t-test and Kruskal-Wallis tests. The exact method of the Chi-square test was used to compare categorical variables. Disease-free and overall survival were assessed using Kaplan-Meier survival analysis and the log-rank test. To determine the factors that influence disease-free and overall survival, Cox regression analysis was used. A p value of <0.05 was considered statistically significant.
RESULTS
Fifty-three patients (64.6%) were male and 29 (35.4%) were female. The mean age was 68.1±1.5 years and the median age was 69 (33-82). The histopathological features of the patients are shown in Table 1 and the surgical methods are shown in Table 2 .
In terms of nuclear immunohistochemical staining of E2F1, 7 cases (8.5%) showed strong staining, 17 cases (20.7%) showed weak staining, and 58 cases (70.7%) showed no staining. When the same cases were evaluated according to whether they Survival rates were compared across different time periods depending on the staining of the nucleus. The mean survival time of the patients with nuclear staining with E2F1 and those without was 39% and 55%, respectively. The relationship between these results was statistically insignificant (p=0.081). Relationship between E2F1 cytoplasmic staining and survival rates was also investigated. The average overall survival rate of the cases with E2F1 cytoplasmic staining was 48% and that of cases without E2F1 cytoplasmic staining was 56%. These differences were statistically insignificant (p=0.408) ( Table 3) .
Survival was investigated according to the degree of nuclear staining: strong and weak nuclear staining. When two groups were compared according to their degree of staining, there was a significant difference between the group with strong nuclear staining and that with weak staining (Table 4) When the patients were evaluated according to the stage and E2F1 nuclear staining, no significant difference was found between them (p=0.212) ( Table 5) . Similarly when the cases were classified according to the degree of nuclear staining (as stained weakly or strongly) and were compared with stage, no significant difference was found between the groups (p=0.170). Patients were evaluated according to the stages in terms of E2F1 cytoplasmic staining and no statistically significant difference was found between the two groups (p=0.802).
When the patients were classified according to the degree of cytoplasmic staining (as weak, medium, and strong stained) and were compared with the stages, there were no statistically significant results (p=0.766).
Fourteen patients (17.1%) received adjuvant chemoradiotherapy. There was no significant survival difference according to the nuclear staining degree in patients who received adjuvant chemoradiotherapy (p=0.22).
The relationship of age, tumor size, nuclear and cytoplasmic staining with survival was evaluated by Cox regression analysis. There was no statistically significant difference between tumor diameter and cytoplasmic staining, but there was a statistically significant difference between age and severity of nuclear staining (p=0.022). When the patients were evaluated according to the severity of nuclear staining, patients with a strong degree of nuclear staining had a 2.317-fold increase in the likelihood of survival compared with patients with a weak degree of nuclear staining.
DISCUSSION
One of the necessary steps in the treatment of the cancer is the development of molecular markers that help predict survival, potential behavior, and aggressiveness of the tumor. In Table 3 . Survival rates according to nuclear and cytoplasmic staining (17) (18) (19) . E2F1 is a transcription factor that has been studied in many tumor types, except for rectal tumors, for its prognostic value.
E2F transcription factor 1 has a role in the G1/S phase transition of the cell cycle. In the transition of G1/S, Rb-E2F complexes are separated and E2F1 starts activating the transcription of many genes required for mitosis. The cyclin-dependent kinase-cyclin complex causes the separation of the Rb-E2F complex with Rb phosphorylation (20) (21) (22) . P16 is a tumor suppressor gene product that prevents the creation of a complex between cyclin and cyclin-dependent kinase (23). Dong et al. (24) showed that E2F1 induces apoptosis in both normal and malignant cells. They also demonstrated that E2F1-dependent apoptosis could be independent of p53. Gene transfer to adenovirus with E2F1 is also effective in antitumor activity, with lower doses of chemotherapeutic agents (25) . In the study of Xie et al. (26) , E2F1 (+) plasmids were transfected into cells and it was shown that apoptosis increases, cell growth slows, and the cell cycle stops at the G2/M phase in gastric cancer. It is thought that E2F1 has a function as a tumor suppressor. La Belle et al. (5) investigated the role of E2F1 in programmed cell death. However, it has not been clearly elucidated if it works as an oncogene or a tumor suppressor. Bramis et al. (4) suggested that E2F1 was a tumor suppressor in colon cancer. Lee et al. (9) reported that in gastric cancer patients, the reactivity of E2F1 can predict overall survival rates independently.
In our study, when patients are grouped as E2F1 nuclear stained or not, the average survival of the E2F1 stained group is 39% and that of the unstained group is 55%. These results were statistically insignificant (p=0.081). If patients were evaluated according to their degree of nuclear staining, the median overall survival of cases with strong nuclear staining was 60% and that for those with weak nuclear staining was 28%. There was a statistically significant difference between the groups according to their degree of nuclear staining (p=0.017). These findings showed that the degree of staining is more decisive according to the presence of staining, for more influence, more E2F1 nuclear staining activity is necessary. The answer to the question why there is a significant difference in survival between strong staining and unstained groups remained to be elucidated with larger studies. When E2F1 cytoplasmic staining was evaluated, the average survival rate of the cytoplasmic staining-positive group was 48% and the average survival rate of the unstained group was 56%. This difference was statistically insignificant (p=0.408). It is suggested that the main effect of E2F1 is on the core. When the correlations between the stages of the disease and nuclear or cytoplasmic stainings were evaluated, any significant difference was not obtained according to both the intensity of the staining and staining alone. Because there was no correlation between E2F1 staining of either nucleus or the cytoplasm and the stages, we may assume that E2F1 plays a role independently from the stage, which means that in some tumors, tumor progression is not dependent on E2F1, whereas in some tumors, E2F1 plays a role from the beginning of the process. Further studies are certainly warranted to address this issue.
Cox regression analysis was used to evaluate the association of age, tumor diameter and cytoplasmic staining with survival. No statistically significant difference was found between tumor diameter and cytoplasmic staining, but the difference between age and degree of nuclear staining was statistically significant (p=0.022). Patients with a strong degree of nuclear staining had a 2.3-fold increase in chances of survival compared with patients with weak staining (p=0.010). These findings suggest that E2F1 does not stimulate cellular proliferation and differentiation but increases apoptosis in rectal cancer as in colon and prostate cancer.
CONCLUSION
As a result, E2F1 is effective, depending on the cell type and signals, and can act as an oncogene or tumor suppressor. It is found to be a poor prognostic parameter in lung, breast, esophageal, and pancreatic cancer, but it also has a protective effect by increasing apoptosis in colon, bladder, and prostate cancer.
Despite the relatively small number of cases, as the first study in the literature, our study demonstrated that E2F1 is a molecular marker that may predict the behavior and aggression of rectal cancer. 
